Evaluate the efficacy of self-amplifying RNA vaccines

The gap

Evidence profile

Sourced from the future work and future-work section of the source papers, classified as general, spanning 3 journals.

Supporting evidence — 4 representative gaps

• Advancing regenerative medicine with RNA nanotechnology for chronic and end organ diseases (2026) · Communications Medicine · doi

  higher translational capacity than unmodified mRNAs. Also, only the unmodified mRNAs depicted immunogenic behavior with elevated levels of interferon α as opposed to the modified mRNAs71. To understand this, researchers have extensively studied selfamplifying RNA (saRNA) versus mRNA for the development of vaccines and how different cargos are sensed intracellularly to produce the immune response. Researchers have been studying whether different RNAs have shown variations in the optimal parameters for cellular activation, and the studies indicated that most parameters remained the same irrespective of the RNA; however, the size of RNA had an impact on the encapsulation efficacy and eventually the mechanism of action. Also, researchers are employing second and third-generation chemical modifications, such as 2′- ribose modifications on siRNAs and phosphoramidate morpholino oligomers (PMOs), to reduce the associated immunogenicity by neutralizing charge and restricting protein interactions that could trigger immune system activation72–75. Most importantly, the stability and rapid degradation of RNAs critically determine the fate of the nanoparticle in the body. Many researchers have been studying ways to improve the RNA half-life for optimal efficacy. Reports have indicated the importance of the Cap, untranslated regions (UTRs), and poly(A) tail located at the 5′- and 3′- ends of the mRNA structure for stable and effective mRNA. Some of the ways to improve mRNA stability include (a) increasing G-C fractions in mRNA, and (b) finetuning the poly(A) tail, 5′ Cap, 5′-UTR/3′-UTR, and rare codon76. Similarly, chemical modifications on siRNAs and ASOs also enhance RNA stability and protect them from rapid nuclease degradation. The most common ASO and siRNA modification is a phosphorothioate modification that enhances DNase resistance and improves cellular uptake due to an increase in hydrophobicity77–79. Additionally, several other potential solutions are being investigated, such as performing more in-depth immune-related adverse event screening in human studies with TLR interaction methods, using short 7–8 nucleotide RNAs that show successful low immunogenicity in preclinical studies, administering metronomic (regular and frequent) doses of RNA therapy, and combination treatments of RNA and immune-based therapies. Overall, the lessons learnt from the COVID-19 mRNA vaccine are important to drive RNA nanotherapeutics in autoimmune diseases, inflammatory conditions, and end-organ diseases as regenerative medicine. Barriers to clinical translation: understanding the factors contributing to the translational gap in chronic and end-organ diseases for regenerative medicine Most importantly, a better understanding of the underlying disease mechanisms is needed for the successful clinical translation of regenerative medicine.

  generalfuture workevidence 5/5
  Keywords: modi mrna researchers immune regenerative medicine mrnas rnas cations stability translational unmodi different studying optimal
• mRNA vaccines against viral pathogens: molecular design, delivery systems, and clinical applications (2026) · Frontiers in Microbiology · doi

  Fundamental concepts and current challenges In the context of advancing mRNA vaccine strategies for viral immunity, several key challenges and future directions emerge from this synthesis. As summarized above, existing mRNA vaccines still encounter challenges, such as poor stability, which requires ultra-low temperature storage and transportation (Yang et al., 2023). This drawback limits their application in regions with limited resources. The delivery efficiency is still not optimal, as a substantial amount of mRNA is retained and degraded within endosomes, which impairs expression and immune activation. This can lead to local or systemic inflammatory reactions, such as hypersensitivity reactions and myocarditis (Jaggers and Wolfson, 2023; Oster et al., 2022).

  generalfuture workevidence 5/5
  Keywords: challenges mrna still reactions fundamental concepts current context advancing vaccine strategies viral immunity several future
• mRNA vaccines against viral pathogens: molecular design, delivery systems, and clinical applications (2026) · Frontiers in Microbiology · doi

  Fundamental concepts and current challenges In the context of advancing mRNA vaccine strategies for viral immunity, several key challenges and future directions emerge from this synthesis. As summarized above, existing mRNA vaccines still encounter challenges, such as poor stability, which requires ultra-low temperature storage and transportation (Yang et al., 2023). This drawback limits their application in regions with limited resources. The delivery efficiency is still not optimal, as a substantial amount of mRNA is retained and degraded within endosomes, which impairs expression and immune activation. This can lead to local or systemic inflammatory reactions, such as hypersensitivity reactions and myocarditis (Jaggers and Wolfson, 2023; Oster et al., 2022).

  generalfuture workevidence 5/5
  Keywords: challenges mrna still reactions fundamental concepts current context advancing vaccine strategies viral immunity several future
• Enhanced immunogenicity and dose-sparing efficacy of self-amplifying RNA vaccines against seasonal influenza across subtypes (2026) · Figshare · doi

  Further studies are needed to evaluate the efficacy of self-amplifying RNA vaccines in human trials. The development of mRNA vaccine candidates targeting emerging influenza strains is necessary. The mechanisms underlying the enhanced immunogenicity of self-amplifying RNA vaccines require further investigation.

  generalfuture-work sectionevidence 5/5
  Keywords: further studies needed evaluate efficacy self-amplifying rna vaccines

Questions about this gap